The main thing is that Eileen Holderman, Maryanne Fletcher, and a third person were threatened with expulsion from the CFSAC.
To be accurate, the key word to add to that sentence would be 'allegedly'...especially pertinent since there has already been mention that lawyers have been spoken to...
I think we should be very cautious in a situation like this before we jump to any conclusions. We don't know what was said, or by whom, or why. All we have is what Holderman and Fletcher said and we haven't heard the context or the other side of that conversation. Eileen was clearly very upset, she said she was afraid to speak out, felt bullied, thought she was being 'shut down' and she and others were being shut out, and she said that she and 2 other committee members had been called (by Nancy Lee, we think, but don't know) and were (according to my notes) 'under threat of expulsion from CFSAC'. Mary-Ann Fletcher said she was one of the three who were called. We don't know when this happened. Crucially, we don't know what reasons lay behind what was said to these three committee members.
Holderman was clearly very passionate about representing the views of patients during this meeting and I'm sure we are all very grateful to her for that, and appreciate many of the things she said. Similarly Fletcher said a lot of really good things and asked a lot of very pertinent questions. It's natural that we see them as being 'on our side' and want to support them, and that's right, I'm not saying we shouldn't do that. However, I do think it is better for everyone concerned if we do our best to try to take some of the heat out of the situation right now, and don't just all pile in and get involved in a fight we don't understand.
We actually don't know whether the 'threats' of expulsion were directly related to the issue around the NIH 'hijack' (as Holderman called it) of the committee's recommendation of a stakeholders workshop to agree a consensus case definition.
Here's an example (paraphrased from my own experience in completely different, non-ME/CFS contexts) of the sort of thing that might (for all we know) have happened. Those 'threats' (hypothetically) could have arisen in the context of an argument about the agenda of the committee meeting, in which the committee members concerned challenged the authority of the chair. I can easily imagine a conversation like this: "Well I'm going to talk about it anyway" - "Well I'm sorry but it's not on the agenda and we have other things we have to discuss today" - "Well I'm going to say it anyway" - "Well if you do you'll be out of order" - "Well I will do it" - "Well if you did that you would be breaching procedure and risking expulsion from the committee". That could be construed as a threat.
But that's all speculation, and so far that's all we have really. What is
really important here is the substance of that issue around the NIH 'hijack' of the recommendation, and regrettably the committee doesn't seem to have resolved that discussion. So it's better, I think, if we focus on thinking about what the committee was confronting, which was this recommendation for a stakeholder's workshop on case definition. Here is that recommendation, which was sent to the Assistant Secretary for Health:
CFSAC recommends that you will promptly convene (by 12/31/12 or as soon as possible thereafter) at least one stakeholders’ (Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)experts, patients, advocates) workshop in consultation with CFSAC members to reach a consensus for a case definition useful for research, diagnosis and treatment of ME/CFS beginning with the 2003 Canadian Consensus Definition for discussion purposes
The response:
The National Institutes of Health(NIH) is convening an Evidence-based Methodology Workshop process (outlined in
recommendation 3b) to address the issue of case definitions appropriate for ME/CFS research. However, it will not cover in detail a clinical case definition. The Office of the Assistant Secretary for Health, Department of Health and Human Services, is actively pursuing options for a separate effort that would work in coordination with the NIH process, but result in a case definition useful for clinicians who see patients with symptoms that may be ME/CFS.
Susan Maier, in answer to questions, did explain that the NIH study was not a case definition workshop (which the committee had requested), and she also mentioned something to the effect that the process towards establishing that workshop had already been underway before the committee had made its recommendation. The process that the NIH is going through is a standard methodology they have in place which is appropriate for reviewing evidence about case definitions; as I understand it, the process will produce evidence about where the gaps are in the case definitions and may also illuminate which treatments are most effective for particular symptoms or symptom clusters, so it will be a step towards showing evidence as to what work needs to be done on case definitions, but it's not the same thing as what the committee wants to see now (which is basically the same thing that advocates and orgs want to see).
Now: I may misunderstand, but it really does seem to me from the above that it's a red herring to complain that the NIH's workshop is not the workshop that the committee is asking for in its recommendation. The NIH's workshop sounds to me like a very good thing indeed, in itself, and neither Susan Maier nor the office of the secretary have pretended that it is a complete answer to the question posed in the committee's recommendation. What they did say was:
The Office of the Assistant Secretary for Health, Department of Health and Human Services, is actively pursuing options for a separate effort that would work in coordination with the NIH process, but result in a case definition useful for clinicians who see patients with symptoms that may be ME/CFS.
Since that response was given in or around January of this year (2013), in answer to the Oct 2012 CFSAC recommendation, it would have been appropriate for the committee to get an update on that separate effort that is being 'actively pursued', and perhaps table a further recommendation, or re-iterate the previous one, saying that this should be a high priority and making clear some of the details about what form it should/must take.
As far as I could tell, the committee failed to do that because it got bogged down in arguing about the NIH workshop not being what it asked for, and I think a large part of the reason for that was lack of time on the agenda. It seems to me that this is the biggest thing that the committee needs to work on: careful and detailed follow-up on the responses to its recommendations, re-iteration of recommendations where responses are inadequate, detailed examination of the text of recommendations and responses, and perhaps most importantly a good structure for doing that as a matter of routine during its meetings. Useful though the information sessions are (such as the medical insurance presentation and the discussion about clinical practice) I would prefer to see the committee focus the vast majority of its time on substantive and constructive discussions about the recommendations and the responses to them - since that is the primary if not sole purpose of the committee.